Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?

1
5 Answers

Mednet Member
Mednet Member
Rheumatology · Berkshire Health Systems

Nope. IVIG preparations contain IgG not IgA or IgM. Low serum IgA may or may not be associated with low IgA levels in mucosal surfaces leading to a risk of local infections. Low levels of one or both may be asymptomatic but in the right setting might suggest a need for evaluation of plasma cell dysc...

What GDMT do you recommend for patients with AL amyloidosis and systolic heart failure?

2 Answers

Mednet Member
Mednet Member
Cardiology · Memorial Sloan Kettering Cancer Center

You are correct that cardiac amyloidosis patients do not tolerate most of the GDMT. SGLT2i may be helpful for both diuresis as well as HFpEF, and we do try to start this. Generally, they do not tolerate ARB/ACEI or even beta blockers. We find that torsemide seems to have better GI absorption and thu...

How do you approach patients who are inappropriately worried/fixated on a test result that is flagged as abnormal but not clinically significant?

3 Answers

Mednet Member
Mednet Member
Hematology · University of Rochester Cancer Center

I emphasize that the reference range intentionally excludes normal individuals who are a little different from the average person, and that the reference range is just a numerical exercise and general guidance, not something that was ordained by higher powers. I don't use the analogy for patients, b...

For atrial fibrillation patients with high risk of CVA who cannot tolerate full dose AC due to bleeding, do you consider low dose/extended dosing anticoagulation even if they do not meet age/GFR criteria for a dose reduction, if Watchman is not readily available as an option?

1 Answers

Mednet Member
Mednet Member
Cardiology · Lankenau Heart Group

Most drugs, including anticoagulants, have a dose-response. Therefore, one could argue that even though DOACs were not studied at low doses, except in defined sub-groups such as the very elderly, using such a dose in other situations may have some benefit. The problem is that without data, we simply...

What is your approach to managing iron overload in children with transfusion-dependent beta thalassemia who have adherence challenges or toxicity with standard chelation regimens?

1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Weill Cornell Medical College

I would divide the adherence issues into two populations. The younger children where a caregiver is responsible for administering the chelation, and adolescents where caregivers have passed on the responsibility to the patient. For the former, adherence is reinforced with an explanation of the possi...

After prior BTKi + venetoclax and subsequent progression, how do you then choose next line therapy for high risk CLL?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Kansas Cancer Center

If the patient received time-limited BTKi + BCL-2 and was in remission at the time of discontinuation, then frequently we consider re-treatment as either BTK monotherapy, BCL-2 + anti-CD20, or BTK + BCL-2. Many of these patients will remain sensitive to both agents. You did not ask about how long th...

In your practice, what premedications do you use for subcutaneous daratumumab?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Chicago

We administer the following pre-infusion medications 1 hour to 3 hours before the first 4 SQ infusions, and then we drop all premedications (except for dexamethasone) thereafter: Dexamethasone 20-40 mg Acetaminophen 650 mg Diphenhydramine 25 mg Montelukast 10 mg [this is not in the package insert b...

For patients with newly diagnosed unmutated CLL how will you decide between BTKi alone vs Ven/BTKi vs Ven/Obin vs Ven/Obin/Acalabrutinib?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · Dana-Farber Cancer Institute

My usual practice has been Ven Obin for most patients, even unmutated, but if they have bulky nodes and are young/fit, I am now adding acala to that and giving the 3-drug regimen. Continuous BTKi in my practice is mostly reserved for the older or less fit patients, or those who really, really don’t ...

What is your approach to VTE prophylaxis in hospitalized patients who are already on DAPT?

2
1 Answers

Mednet Member
Mednet Member
Hospital Medicine · University of California San Francisco

DAPT by itself is not considered DVT prophylaxis in patients at high risk of DVT. However, LMWH at prophylactic doses can increase the need for transfusions in patients on DAPT, without decreasing VTE rates. In general, I consider patients individually: Do they still need DAPT? With discontinuity o...

Do you routinely check serum phosphorus levels after IV iron therapy?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Virginia Mason Medical Center

I do not routinely monitor serum phosphorus levels after intravenous iron therapy if ferric carboxymaltose (FCM) is not being administered. At our institution, the top two formulary choices for outpatient use for iron repletion are iron sucrose and ferumoxytol, neither of which is associated with a ...